130642-50-1 Usage
Description
Loratadine ketone, also known as [3-[2-(3-Chlorophenyl)ethyl]-2-pyridinyl](1-methyl-4-piperidinyl)methanone, is an impurity found in Loratadine (L469575), a non-sedating antihistamine medication that targets the histamine H1-receptor. It is derived from the pharmaceutical compound Loratadine and is used in the study and development of antihistamine drugs.
Uses
Used in Pharmaceutical Industry:
Loratadine ketone is used as an impurity in the development and production of Loratadine, a non-sedating antihistamine. It plays a role in the study of the drug's properties, effects, and potential side effects, contributing to the overall understanding and improvement of Loratadine's efficacy and safety.
Additionally, Loratadine ketone may be used in the research and development of new antihistamine medications, as understanding its properties can help in the design and synthesis of novel compounds with similar or improved therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 130642-50-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,4 and 2 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 130642-50:
(8*1)+(7*3)+(6*0)+(5*6)+(4*4)+(3*2)+(2*5)+(1*0)=91
91 % 10 = 1
So 130642-50-1 is a valid CAS Registry Number.
130642-50-1Relevant articles and documents
Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine
Kaminski, James J.,Carruthers, Nicholas I.,Wong, Shing-Chun,Chan, Tze-Ming,Motassim Billah,Tozzi,McPhail, Andrew T.
, p. 1413 - 1423 (2007/10/03)
Following the discovery of the first dual antagonist of platelet-activating factor (PAF) and histamine, 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine, Sch 37370, 1, a related series of structures, exemplified by (±)-1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-yl)piperazine, Sch 40338, 2, were prepared. Interestingly, the compounds exhibited a parallel structure-antiallergy activity relationship, suggesting that the two series may adopt a common conformation at the PAF receptor. Conformational analysis led to a proposal for this bioactive conformation accessible to both series. The synthesis of novel conformationally constrained analogues that might mimic the proposed bioactive conformation of these compounds, and the evaluation of their in vitro antiallergy activity form the subject matter of this report. Copyright (C) 1999 Elsevier Science Ltd.